Filter Results
:
(26)
Show Results For
-
All HBS Web
(115,773)
- Faculty Publications (26)
Show Results For
-
All HBS Web
(115,773)
- Faculty Publications (26)
←
Page 2 of
26
Results
- August 2023 (Revised August 2023)
- Case
Morphic Therapeutic: Making the Initial Pipeline Decisions
By: Satish Tadikonda and Ananya Zutshi
- August 2023
- Case
Sky Therapeutics: Innovating in Digital Therapeutics
By: Satish Tadikonda and Olivia Reszczynski
Shad Faraz and Alex Youssef were intrigued by the opportunities in the relatively new area of Digital Therapeutics. Despite initial successes, early entrants had struggled with reimbursement and revenue-predictability challenges. However, venture investors still...
View Details
Keywords:
Business Startups;
Entrepreneurship;
Mission and Purpose;
Health Industry;
Technology Industry
Tadikonda, Satish, and Olivia Reszczynski. "Sky Therapeutics: Innovating in Digital Therapeutics." Harvard Business School Case 824-023, August 2023.
- July 2023
- Case
HealthVerity: Real World Data and Evidence
By: Satish Tadikonda
Andrew Kress (CEO and founder) and his team had built a promising marketplace business at HealthVerity serving its core market in healthcare, with a focus on pharmaceutical R&D and services. Thus far, HealthVerity’s products had been unique to the pharma and pharma...
View Details
Tadikonda, Satish. "HealthVerity: Real World Data and Evidence." Harvard Business School Case 824-019, July 2023.
- July 2023 (Revised December 2023)
- Case
Miracle Therapeutics (A): Negotiating an IP License
By: Satish Tadikonda, Michael Singer, William Marks and Wendi Yajnik
(General Experience Case) Beth Sharp and Jennifer Brilliant founded Miracle Therapeutics based on intellectual property developed by Brilliant and her post-doctoral student, John Supreme, in Brilliant’s lab at Elite University (EU). Miracle will have to obtain a...
View Details
Tadikonda, Satish, Michael Singer, William Marks, and Wendi Yajnik. "Miracle Therapeutics (A): Negotiating an IP License." Harvard Business School Case 824-020, July 2023. (Revised December 2023.)
- July 2023
- Case
Moderna: Everything, Everywhere, All at Once
By: Satish Tadikonda, Shikhar Ghosh and William Marks
Coming out of the COVID-19 pandemic, Moderna was riding the successes of developing a vaccine in record time and helping stem the tide of the crisis. However, the company had grown at an incredible rate, more than doubled its number of employees, and had to put on hold...
View Details
Tadikonda, Satish, Shikhar Ghosh, and William Marks. "Moderna: Everything, Everywhere, All at Once." Harvard Business School Case 824-021, July 2023.
- February 2022 (Revised November 2022)
- Case
Nuritas
By: Mitchell Weiss, Satish Tadikonda, Vincent Dessain and Emer Moloney
Nora Khaldi had built a technology “to unlock the power of nature” in the service of extending human lifespan and improving health, and now in April 2020 was debating telling her Board of Directors she wanted to put on ice some of her discoveries. Nuritas, the company...
View Details
Keywords:
Cash Burn;
Cash Flow Analysis;
Pharmaceutical Companies;
Founder;
Artificial Intelligence;
AI;
Entrepreneurship;
Health Testing and Trials;
Health Care and Treatment;
Decision Making;
Market Entry and Exit;
AI and Machine Learning;
Pharmaceutical Industry
Weiss, Mitchell, Satish Tadikonda, Vincent Dessain, and Emer Moloney. "Nuritas." Harvard Business School Case 822-080, February 2022. (Revised November 2022.)